Precision Optics Reports Second Quarter Fiscal Year 2024 Financial Results
- Revenue decreased by 18% to $4.8 million compared to the same quarter last year.
- Engineering revenue increased by 33% to $2.3 million.
- Production revenue was $2.6 million compared to $3.6 million in the previous year.
- Gross margins decreased to 30.1% from 44.2% due to the impact of technology rights revenue.
- Net loss for the quarter was ($758,802) compared to a net income of $508,668 in the same quarter last year.
- Adjusted EBITDA was ($269,034) compared to $866,450 in the same quarter last year.
- The company signed production and technology license agreements with major medical device and surgical robotics companies.
- CEO Joseph Forkey highlighted the rebound in revenue, margin issues, and growth prospects for the second half of fiscal 2024.
- Revenue declined by 18%, signaling potential challenges in sales performance.
- Gross margins decreased to 30.1%, impacting profitability.
- Net loss of ($758,802) indicates financial strain.
- Adjusted EBITDA decreased to ($269,034) compared to the same quarter last year.
- Operating income showed a loss of ($704,162).
Insights
The reported 18% decrease in revenue alongside a net loss of $758,802 for Precision Optics Corporation is a critical factor for stakeholders, indicating potential challenges in the company's profitability and operational efficiency. The gross margin decline from 44.2% to 30.1% raises concerns about cost management and pricing power, which could affect future earnings. However, the increase in engineering revenue by 33% suggests a robust pipeline that may translate into future production revenue, offering a possible turnaround narrative for the company.
Investors should monitor the company's ability to resolve margin issues and whether the new programs can sustain a revenue uptick. The company's positioning in high-growth market segments like micro-optics and single-use medical devices may offer long-term growth potential, but this must be weighed against current operational challenges.
From a market perspective, Precision Optics Corporation's focus on advanced optical instruments for the medical and defense industries aligns with sectors that typically see steady demand due to their critical nature. The company's engagement in single-use medical devices and partnerships with technology-focused medical and surgical robotics companies indicates strategic moves to capture emerging market trends, which could be a key driver for future growth.
However, the company's performance must be contextualized within the broader industry trends. If competitors are maintaining or increasing margins while Precision Optics experiences a decline, it could signal operational inefficiencies or pricing pressures that need to be addressed to maintain competitiveness.
The transition to single-use medical devices and advancements in 3D endoscopy reflect Precision Optics Corporation's investment in innovation, which is crucial in the medical device sector. The development of a complex imaging sub-assembly for a next-generation ophthalmoscope and the production agreement for a cystoscopy robotic surgery system highlight the company's technical capabilities and potential for securing a stronghold in niche markets.
Long-term success in this industry depends on continuous R&D investment, maintaining strong relationships with key industry players and navigating regulatory landscapes. The company's engineering revenue growth serves as a positive indicator of its R&D focus, but it's essential to translate these developments into sustainable production revenue and profitability.
Conference Call Scheduled for today, February 14, 2024, at 5:00pm ET.
Q2 2024 Financial Highlights (3 Months Ended December 31, 2023):
- Revenue decreased
18% to$4.8 million $5.9 million 12% from the most recent sequential quarter. The year ago second quarter included a one-time sale of$600,000 - Engineering revenue increased
33% to$2.3 million $1.7 million 19% from the most recent sequential quarter. - Production revenue was
$2.6 million $3.6 million $2.4 million - Gross margins were
30.1% compared to44.2% in the same quarter of the previous year. Removing the impact of the technology rights revenue, gross margins a year ago would have been37.8% . - Net loss for the quarter was (
$758,802 $508,668 - Adjusted EBITDA was (
$269,034 $866,450
Recent Additional Highlights:
- In November 2023, the Company announced the receipt of initial purchase orders towards a
$1.4 million - In December 2023, the Company announced the signing of a production and technology license agreement with a leading surgical robotics company to supply a single-use endoscope assembly used in their cystoscopy robotic surgery system.
Precision Optics' CEO, Joseph Forkey, commented, "The Company's results for Q2 were generally in-line with our expectations and consistent with what we have communicated previously. While revenue was lower compared to last year due to timing differences between reorders for ongoing production, the exit of certain mature customer programs and the introduction of new customer programs, we have begun to see the rebound we expected with two new programs moving to production in the quarter and another restarting after a pandemic-related hold. These programs contributed to a
Dr. Forkey continued, "The growth we expect in the second half of fiscal 2024 is supported by the strength of our engineering pipeline, a leading indicator of future production volumes. Engineering revenue was
The following table summarizes the second quarter and fiscal year to date (unaudited) results for the periods ended December 31, 2023, and 2022:
Three Months | Six Months | |||||
Ended December 31, | Ended December 31, | |||||
2023 | 2022 | 2023 | 2022 | |||
Revenues | ||||||
Gross Profit | 1,450,976 | 2,599,472 | 2,914,587 | 4,238,913 | ||
Stock Compensation Expenses | 382,431 | 108,746 | 491,177 | 319,776 | ||
Other | 1,772,707 | 1,919,661 | 3,532,865 | 3,449,874 | ||
Total Operating Expenses | 2,155,138 | 2,028,407 | 4,024,042 | 3,769,650 | ||
Operating Income (Loss) | (704,162) | 571,065 | (1,109,455) | 469,263 | ||
Net Income (Loss) | (758,802) | (508,668) | (1,223,217) | 349,944 | ||
Income (Loss) per Share | ||||||
Basic | $ (0.13) | $ (0.09) | $ (0.20) | $ 0.06 | ||
Fully Diluted | $ (0.13) | $ (0.09) | $ (0.20) | $ 0.06 | ||
Weighted Average Common Shares Outstanding | ||||||
Basic | 6,066,572 | 5,638,302 | 6,066,545 | 5,638,302 | ||
Fully Diluted | 6,066,572 | 5,935,911 | 6,066,545 | 5,937,471 | ||
Note: The Common Shares in this table reflect shares on a post reverse split basis for all periods presented. | ||||||
Conference Call Details
Date and Time: Wednesday, February 14, 2024, at 5:00pm ET
Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or
(412) 317-5705.
Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available at https://app.webinar.net/5l19x2DzRKG.
Replay: A teleconference replay of the call will be available until February 21, 2024, at (877) 344-7529 or (412) 317-0088, replay access code 9304851. A webcast replay will be available at https://app.webinar.net/5l19x2DzRKG.
About Precision Optics Corporation
Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Lighthouse Imaging division's electronic imaging expertise and its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company designs and manufactures next-generation product solutions to meet the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery, including single-use medical devices, as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies with a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.
Non-GAAP Financial Measures
Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the Unites States of America ("non-GAAP"). The non-GAAP financial measure is Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization). Adjusted EBITDA also excludes from Net Income (Loss) the effect of stock-based compensation, restructuring and other acquisition-related items.
This non-GAAP financial measure assists Precision Optics management in comparing its operating performance over time because certain items may obscure the underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition or restructuring plans that are fundamentally different from the ongoing productivity of the Company. Precision Optics management also believes that presenting this measure allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measure presented above to GAAP results has been provided in the financial tables included with this press release.
About Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company's future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by the Company's management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous risk factors. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement, except as required by law.
Company Contact:
PRECISION OPTICS CORPORATION
22 East Broadway
Telephone: 978-630-1800
Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Telephone: 602-889-9700
poci@lythampartners.com
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (UNAUDITED) | ||||||||
December 31, | June 30, | |||||||
2023 | 2023 | |||||||
ASSETS | ||||||||
Current Assets: | ||||||||
Cash and cash equivalents | $ | 987,044 | $ | 2,925,852 | ||||
Accounts receivable, net of allowance for doubtful accounts of | 3,511,544 | 3,907,407 | ||||||
Inventories | 3,099,986 | 2,776,216 | ||||||
Prepaid expenses | 234,121 | 249,681 | ||||||
Total current assets | 7,832,695 | 9,859,156 | ||||||
Fixed Assets: | ||||||||
Machinery and equipment | 3,253,746 | 3,227,481 | ||||||
Leasehold improvements | 832,305 | 825,752 | ||||||
Furniture and fixtures | 362,287 | 242,865 | ||||||
Total fixed assets | 4,448,338 | 4,296,098 | ||||||
Less—Accumulated depreciation and amortization | 3,966,839 | 3,862,578 | ||||||
Net fixed assets | 481,499 | 433,520 | ||||||
Operating lease right-to-use asset | 275,329 | 358,437 | ||||||
Patents, net | 283,643 | 265,111 | ||||||
Goodwill | 8,824,210 | 8,824,210 | ||||||
TOTAL ASSETS | $ | 17,697,376 | $ | 19,740,434 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current Liabilities: | ||||||||
Current portion of capital lease obligation | $ | 44,519 | $ | 43,209 | ||||
Current maturities of long-term debt | 513,259 | 513,259 | ||||||
Accounts payable | 1,675,742 | 2,432,264 | ||||||
Customer advances | 1,158,242 | 1,174,690 | ||||||
Accrued compensation and other | 747,793 | 927,521 | ||||||
Operating lease liability | 173,503 | 168,677 | ||||||
Total current liabilities | 4,313,058 | 5,259,620 | ||||||
Capital lease obligation, net of current portion | 45,890 | 68,482 | ||||||
Long-term debt, net of current maturities and debt issuance costs | 1,919,350 | 2,175,980 | ||||||
Operating lease liability, net of current portion | 101,826 | 189,760 | ||||||
Stockholders' Equity: | ||||||||
Common stock, | 60,675 | 60,665 | ||||||
Additional paid-in capital | 60,718,801 | 60,224,934 | ||||||
Accumulated deficit | (49,462,224) | (48,239,007) | ||||||
Total stockholders' equity | 11,317,252 | 12,046,592 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 17,697,376 | $ | 19,740,434 | ||||
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE SIX MONTHS ENDED DECEMBER 31, 2023 AND 2022 (UNAUDITED) | ||||||||||||||||
Three Months | Six Months | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Revenues | $ | 4,824,289 | $ | 5,886,961 | $ | 9,145,544 | $ | 10,972,262 | ||||||||
Cost of Goods Sold | 3,373,313 | 3,287,489 | 6,230,957 | 6,733,349 | ||||||||||||
Gross Profit | 1,450,976 | 2,599,472 | 2,914,587 | 4,238,913 | ||||||||||||
Research and Development Expenses | 221,728 | 155,264 | 434,486 | 365,891 | ||||||||||||
Selling, General and Administrative | 1,933,410 | 1,873,143 | 3,589,556 | 3,403,759 | ||||||||||||
– | ||||||||||||||||
Total Operating Expenses | 2,155,138 | 2,028,407 | 4,024,042 | 3,769,650 | ||||||||||||
Operating Income (Loss) | (704,162) | 571,065 | (1,109,455) | 469,263 | ||||||||||||
Interest Expense | (54,640) | (62,397) | (113,762) | (119,319) | ||||||||||||
Net Income (Loss) | $ | (758,802) | $ | 508,668 | $ | (1,223,217) | $ | 349,944 | ||||||||
Loss Per Share: | ||||||||||||||||
Basic | (0.13) | $ | 0.09 | (0.20) | $ | 0.06 | ||||||||||
Fully Diluted | $ | (0.13) | $ | 0.09 | $ | (0.20) | $ | 0.06 | ||||||||
Weighted Average Common Shares | ||||||||||||||||
Basic | 6,066,572 | 5,638,302 | 6,066,545 | 5,638,302 | ||||||||||||
Fully Diluted | 6,066,572 | 5,935,911 | 6,066,545 | 5,937,471 | ||||||||||||
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED DECEMBER 31, 2023 AND 2022 (UNAUDITED) | ||||||||
Six Months | ||||||||
2023 | 2022 | |||||||
Cash Flows from Operating Activities: | ||||||||
Net Income (Loss) | $ | (1,223,217) | $ | 349,944 | ||||
Adjustments to reconcile net loss to net cash used in by operating activities - | ||||||||
Depreciation and amortization | 104,261 | 104,750 | ||||||
Stock-based compensation expense | 491,177 | 319,776 | ||||||
Non-cash interest expense | 8,752 | 16,966 | ||||||
Changes in operating assets and liabilities - | ||||||||
Accounts receivable, net | 395,863 | (1,368,650) | ||||||
Inventories, net | (323,770) | 232,963 | ||||||
Prepaid expenses | 15,560 | 271 | ||||||
Accounts payable | (756,522) | 216,060 | ||||||
Customer advances | (16,448) | (110,132) | ||||||
Accrued compensation and other | (188,480) | 255,162 | ||||||
Net cash (used in) provided by operating activities | (1,492,824) | 17,110 | ||||||
Cash Flows from Investing Activities: | ||||||||
Purchases of fixed assets | (152,240) | (13,583) | ||||||
Additional patent costs | (18,532) | (24,054) | ||||||
Net cash used in investing activities | (170,772) | (37,637) | ||||||
Cash Flows from Financing Activities: | ||||||||
Payments of capital lease obligations | (21,282) | (20,049) | ||||||
Payments of long-term debt | (256,630) | (183,855) | ||||||
Gross proceeds from the exercise of stock options | 2,700 | - | ||||||
Net cash used in financing activities | (275,212) | (203,904) | ||||||
– | ||||||||
Net (decrease) increase in cash and cash equivalents | (1,938,808) | (224,431) | ||||||
Cash and cash equivalents, beginning of period | 2,925,852 | 605,749 | ||||||
Cash and cash equivalents, end of period | $ | 987,044 | $ | 381,318 | ||||
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES | ||||||||||||||||
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES | ||||||||||||||||
ADJUSTED EBITDA | ||||||||||||||||
Three Months | Six Months | |||||||||||||||
Ended December 31, | Ended December 31, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Net Income (loss) (GAAP) | $ | (758,802) | $ | 508,668 | $ | (1,223,217.00) | $ | 349,944 | ||||||||
Stock based compensation | 382,431 | 244,786 | 491,177.00 | 319,776 | ||||||||||||
Depreciation and Amortization | 52,697 | 52,667 | 104,261.00 | 105,078 | ||||||||||||
Interest expense | 54,640 | 60,329 | 113,762.00 | 117,251 | ||||||||||||
Adjusted EBITDA (non-GAAP) | $ | (269,034) | $ | 866,450 | $ | (514,017) | $ | 892,049 | ||||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/precision-optics-reports-second-quarter-fiscal-year-2024-financial-results-302062206.html
SOURCE Precision Optics Corporation
FAQ
What was Precision Optics Corporation, Inc.'s revenue for Q2 2024?
What was the net loss for Precision Optics Corporation, Inc. in Q2 2024?
How did Precision Optics Corporation, Inc.'s gross margins change in Q2 2024?
What agreements did Precision Optics Corporation, Inc. sign in December 2023?
Who is the CEO of Precision Optics Corporation, Inc.?
